Philip Serlin - Purple Biotech Independent Director
KTOV Stock | ILA 17.90 1.80 9.14% |
Director
Mr. Philip Adam Serlin serves as Independent Director at Kitov Pharmaceuticals Holdings Ltd since July 18, 2013. His work experience includes the following roles Chief Financial Officer and Operations Manager at BioLine RX Ltd. He holds a Bachelors degree in Accounting from Yeshiva University and a MBA degree, majoring in Economics and Public Policy from George Washington University. since 2013.
Age | 56 |
Tenure | 11 years |
Professional Marks | MBA |
Phone | 972 3 933 3121 |
Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 11 records | DIRECTOR Age | ||
Michal Preminger | Compugen | N/A | |
JeanPierre Bizzari | Compugen | 64 | |
Gilead Halevy | Compugen | 51 | |
Dov Hershberg | Compugen | 74 | |
Joshua Shemer | Compugen | 63 | |
Arie Ovadia | Compugen | 67 | |
Ruth Arnon | Compugen | 86 | |
Kinneret Savitsky | Compugen | 50 | |
Eran Perry | Compugen | N/A | |
Sanford Zweifach | Compugen | 60 | |
Yair Aharonowitz | Compugen | 73 |
Management Performance
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itzhak Israel, Chief Executive Officer & Director | ||
Steven Steinberg, Independent Director | ||
Gil BenMenachem, Vice President - Business Development | ||
Michael Schickler, Head of Clinical Operations | ||
Philip Serlin, Independent Director | ||
CPA MBA, Strategic Director | ||
Arie Weber, Independent Director | ||
Bertrand Liang, Chief Medical Officer | ||
Yisrael Gewirtz, Internal Auditor | ||
John Waymack, Chairman of the Board & Chief Medical Officer | ||
Ran Tzror, Independent Director | ||
Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
Simcha Rock, CFO, Director | ||
Eric Rowinsky, Chairman of the Board | ||
Moran SherfBlau, External Director | ||
Ido Agmon, Independent Director | ||
Gil CPA, Deputy CFO | ||
Leah Bruck, Director | ||
Isaac Israel, CEO Director | ||
Revital SternRaff, Independent Director | ||
Pinhas BarShmuel, Internal Auditor | ||
Avraham BenTzvi, General Counsel, Secretary | ||
Alain Zeitoun, External Director | ||
Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 | |||
Operating Margin | (7.54) % | |||
Shares Outstanding | 172.11 M | |||
Shares Owned By Insiders | 0.12 % | |||
Shares Owned By Institutions | 1.22 % | |||
Price To Earning | (364.21) X | |||
Price To Book | 1.27 X | |||
Price To Sales | 16.36 X | |||
Revenue | 1000 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Purple Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Purple Biotech's short interest history, or implied volatility extrapolated from Purple Biotech options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Stocks Directory Find actively traded stocks across global markets |